Biotechnology

Angel Yeast Reports Strong Revenue Growth in First Half of 2021, Achieves 20.55% YoY Increase

YICHANG, China, Aug. 3, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast ")(en.angelyeast.com ), a listed high-tech yeast company inChina, today announces its first-half fiscal year 2021 financial and business results endingJune 30, 2021. Highlights of the rep...

2021-08-03 15:54

Nanoform and Boehringer Ingelheim execute master services agreement

HELSINKI, Aug. 3, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development proj...

2021-08-03 14:28 181

GenScript Joins Forces with Allozymes by Providing Smart Libraries Construction for Precision Protein Engineering

SINGAPORE, Aug. 3, 2021 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK) today announced a collaboration with Allozymes, a synthetic biology company transforming ingredient manufacturing by unlocking protein engineering potential through groundbreaking technologies. In this par...

2021-08-03 12:05 581

CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA and considered for Priority Review

* Ivosidenib (TIBSOVO®, the brand name in the U.S.) is the first isocitrate dehydrogenase 1 (IDH1) inhibitor inChina that has demonstrated its efficacy and manageable safety in patients with relapsed or refractory acute myeloid leukemia (R/R AML) * The National Medical Products Administration...

2021-08-03 08:05 722

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP c...

2021-08-02 20:13 695

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

* Nitric oxide has antimicrobial properties with direct proven effect on SARS-CoV-2 * Nitric Oxide Nasal Spray (NONS) has been tested in healthy volunteers and patients as part of UK andCanada clinical trials1 MUMBAI, India and VANCOUVER, BC, Aug. 2, 2021 /PRNewswire/ -- Glenmark Pharmaceutic...

2021-08-02 18:45 635

ElectroPhysiology Frontiers announces appointment of Avi Fischer, M.D. as CEO

MILAN, Aug. 2, 2021 /PRNewswire/ -- ElectroPhysiology Frontiers S.p.A. (EPF), announced that its Board of Directors unanimously appointedAvi Fischer, M.D. as Chief Executive Officer (CEO) of the company and a member of its Board of Directors. EPF is a medical technology company developing an inn...

2021-08-02 18:00 536

Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers

HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

2021-08-02 17:00 569

Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently ...

2021-08-02 14:00 582

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...

2021-08-02 07:29 2591

EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine

HONG KONG, July 30, 2021 /PRNewswire/ -- EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group inHong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limit...

2021-07-30 15:33 6888

Neukio Biotherapeutics completed its $40m Angel round financing, focusing on the development of iPSC-CAR-NK platform and assets.

SHANGHAI, July 30, 2021 /PRNewswire/ -- Neukio Biotherapeutics, a newly established company, recently announced the completion of its$40m Angel round of financing led byLilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments. The fund will be used mainly for the es...

2021-07-30 08:00 833

Global Cord Blood Corporation Files Annual Report on Form 20-F

HONG KONG, July 30, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company filed its Annual ...

2021-07-30 04:16 8796

MGI Australia Demo Lab Opens to Support APAC Customers

BRISBANE, Australia, July 29, 2021 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a world-leading life science technology innovator, announces the opening of MGI Australia Demonstration Laboratory (Demo Lab) to support the users inAustralia and New Zealand (ANZ). The lab is...

2021-07-29 19:18 855

Exyte Empowers the Biopharmaceutical Industry: First ExyCell(R) Facility Launched in Shanghai

STUTTGART, Germany and BERGISCH GLADBACH, Germany, July 29, 2021 /PRNewswire/ -- Exyte has successfully completed the construction of the first ExyCell®  facility inChina, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products...

2021-07-29 16:25 813

BIOTRONIK Applauded by Frost & Sullivan for Its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm

LONDON, July 28, 2021 /PRNewswire/ -- Based on its recent analysis of the Global market for implantable cardiac monitoring devices,Frost & Sullivan recognizesBIOTRONIK with the 2021 Global Enabling Technology Leadership Award. The company's subcutaneous miniature, injectable electrocardiogram (EC...

2021-07-28 18:00 621

Deep Longevity Repurposes a Blood Aging Clock for Saliva Samples

HONG KONG, July 27, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly owned subsidiary Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to ann...

2021-07-27 21:39 12598

Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions

 -- Major investments are expanding manufacturing capacity for life sciences products at 13 Cytiva and Pall Corporation sites helping to meet customer demand. -- New sites opening in US and UK to realize regional manufacturing models. Overall, the companies plan to hire 2000 full-time associates...

2021-07-27 14:05 1415

Deep Longevity Releases an AI-based Predictor of COVID Time-To-Death

HONG KONG, July 26, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly-owned subsidiary Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to ann...

2021-07-26 19:08 3960

Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors

HOUSTON and SINGAPORE, July 26, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr,...

2021-07-26 17:00 662
12345 ... 103